EORTC OSN/CTOS11 Safety of Caelyx combined with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas. Final.

Slides:

Advertisements

Similar presentations

FOLFOXIRI plus bevacizumab (bev) vs FOLFIRI plus bev

Advertisements

I I. B.- T R E A T M E N T P L A N: DOCETAXEL 75 mg/m2 40 mg/m2 THORACIC RT (66 Gys: 180 cGy/d) CISPLATIN 40 mg/m2 Days E V A L U A.

Brown JR et al. Proc ASH 2013;Abstract 523.

A pooled analysis of the final results of the two randomized phase II studies comparing Gemcitabine (G) vs Gemcitabine + Docetaxel (G+D) in patients (pts)

LMS-02 A phase II single-arm multicenter study of Trabectedin in combination with Doxorubicin as first-line treatment of metastatic and/or locally advanced.

Herceptin® (trastuzumab) in combination with chemotherapy: pivotal metastatic breast cancer survival data 1.

Introduction  Soft Tissue Sarcoma (STS) are a group of highly chemotherapy resistant tumors  Doxorubicin is the only APPROVED 1 st line chemotherapy.

Targeting Tumors Using Endogenous Albumin

Presented by Martin H. Cohen, M.D. at the 27 July 2004 meeting of the Oncologic Drugs Advisory Committee.

Efficacy of Denileukin Diftitox Retreatment in Patients with Cutaneous T-Cell Lymphoma Who Relapsed After Initial Response 1 Identification of an Active,

A Meta Analysis of Risk of Cardiovascular Events in Patients with Metastatic Breast Cancer (MBC) Treated with Anti Vascular Endothelial Growth Factor (VEGF)

Phase III Study Comparing Gemcitabine plus Cetuximab versus Gemcitabine in Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma Southwest.

Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single agent (s/a) BEV as maintenance therapy in.

A phase I study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities.

1 Phase II trial of sequential gemcitabine and carboplatin followed by paclitaxel as first-line treatment of advanced urothelial carcinoma Presented by.

Taxane-pretreated metastatic breast cancer (MBC): investigational agents TTP = median time to disease progression OS = median overall survival.

Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy in first-line human epidermal growth factor receptor.

Randomized phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas (TRS) Sant P. Chawla,

ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP inhibitor, Niraparib and Temozolomide in Patients with Previously Treated,

Capecitabine versus Bolus 5-FU/Leucovorin as Adjuvant Therapy for Colon Cancer: X-ACT Trial Results James Cassidy, MD Colorectal Cancer Update Think Tank.

1 SNDA Gemzar plus Carboplatin Treatment of Late Relapsing Ovarian Cancer.

Results of Docetaxel Plus Oxaliplatin (DOCOX) +/- Cetuximab in Patients with Metastatic Gastric and/or Gastroesophageal Junction Adenocarcinoma: Results.

Predicting toxicity for patients with advanced Gastrointestinal Stromal Tumors (GIST) treated with imatinib mesylate : an EORTC/ISG/AGITG randomized trial.

Phase III trial of chemotherapy with or without irinotecan in the front-line treatment of metastatic colorectal cancer in elderly patients. FFCD

Randomized Phase III Trial Comparing FOLFIRINOX (F: 5FU/Leucovorin [LV], Irinotecan [I], and Oxaliplatin [O]) versus Gemcitabine (G) as First-Line Treatment.

Phase I/II Trial of Docetaxel plus Oxaliplatin and 5-Fluorouracil (D-FOX) in Patients with Untreated, Advanced Gastric or Gastroesophageal Cancer Jaffer.

Outcome of chemotherapy in synovial sarcoma (sys) patients (pts): review of 15 clinical trials from EORTCc involving advanced sys compared to other Soft.

EARLY PROGRESSION IN PATIENTS WITH HIGH-RISK SOFT TISSUE SARCOMAS AN ANALYSIS FROM A PHASE III RANDOMIZED PROSPECTIVE TRIAL (EORTC 62961/ESHO) OF NEOADJUVANT.

Ibrutinib in Combination with Bendamustine and Rituximab Is Active and Tolerable in Patients with Relapsed/Refractory CLL/SLL: Final Results of a Phase.

MAX: International multi-centre randomised phase II/III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for.

Ruan J et al. Proc ASH 2013;Abstract 247.

AVADO TRIAL David Miles Mount Vernon Cancer Centre, Middlesex, United Kingdom A randomized, double-blind study of bevacizumab in combination with docetaxel.

The Combination of Bevacizumab (Bev) with capecitabine/irinotecan (CapIri/Bev) or capecitabine/oxaliplatin (CapOx/Bev) is highly active in advanced colorectal.

Activation of insulin like growth factor 1 receptor (IGF-1R) signaling pathway is implicated in proliferation, survival, and angiogenesis in pancreatic.

Correlation of Hand-Foot Skin Reaction (HFS) with Treatment Efficacy in Pancreatic Cancer (PC) Patients (pts) Treated with Gemcitabine/Capecitabine plus.

Maintenance Therapy with Bortezomib plus Thalidomide (VT) or Bortezomib plus Prednisone (VP) in Elderly Myeloma Patients Included in the GEM2005MAS65 Spanish.

Phase II trial of irinotecan/docetaxel for advanced pancreatic cancer with randomization between irinotecan/docetaxel and irinotecan/docetaxel plus C225,

Phase II trial of chemotherapy with high-dose FOLFIRI plus bevacizumab in the front-line treatment of patients with metastatic colorectal cancer (mCRC)

Raafat R. Abdel-Malek, MD, FRCR Ass. Prof Clinical Oncology Cairo University, Egypt Efficacy & Toxicity of Sunitinib in mRCC patients in Egypt.

A Phase 2 Study with a Daily Regimen of the Oral mTOR Inhibitor RAD001 (Everolimus) in Patients with Metastatic Clear Cell Renal Cell Cancer Amato RJ et.

12 th Annual CTOS Meeting 2006 AP23573 Induced Long-term Stability in 2 Patients with Desmoplastic Small Round Cell Tumor (#561) Scott Schuetze, Warren.

CALYPSO Trial: Carboplatin & Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin & Paclitaxel in Relapsed, Platinum- Sensitive Ovarian Cancer Pujade-Lauraine.

Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results.

P.A. Tang 1, S. J. Cohen 1, G. Bjarnason 1, C. Kollmannsberger 1, K. Virik 1, M. J. MacKenzie 1, J. Brown 1, L. Wang 1, A. Chen 2, M. J. Moore 1 1 Princess.

1 A Randomized, Multi-Center Phase III Trial of Irinotecan in Combination with Three Different Methods of Administration of Fluoropyrimidine with Celecoxib.

Phase II Trial of R-CHOP plus Bortezomib Induction Therapy Followed by Bortezomib Maintenance for Previously Untreated Mantle Cell Lymphoma: SWOG 0601.

Journal Club Dr. Eyad Al-Saeed Radiation Oncology 12 January, 2008.

Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib:

1 NDA Clofarabine Cl-F-Ara-A Presented by Martin Cohen, M.D. at the December 01, 2004 meeting of the Oncologic Drugs Advisory Committee meeting.

Brentuximab Vedotin in Combination with RCHOP as Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study Yasenchak CA et al. Proc.

Mok TS, Wu SL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361: Gefitinib Superior.

Erlotinib plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute.

Results of a Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic HER2-Negative Breast.

Single-agent nab-Paclitaxel Given Weekly (3/4) as First-line Therapy for Metastatic Breast Cancer (An International Oncology Network Study, #I )

Romidepsin in Association with CHOP in Patients with Peripheral T-Cell Lymphoma: Final Results of the Phase Ib/II Ro-CHOP Study Dupuis J et al. Proc ASH.

Esophageal Cancer: A Critical Evaluation of Systemic Second-Line Therapy Christiane Maria Rosina Thallinger, Markus Raderer, and Michael Hejna J Clin Oncol.

12 th Annual CTOS Meeting 2006 SINGLE AGENT DOXORUBICIN VS DOSE INTENSIVE COMBINATION THERAPY WITH EPIRUBICIN / IFOSFAMIDE IN PREVIOUSLY UNTREATED ADULT.

Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone inpatients with advanced non-small cell lung cancer and a performance status.

Alessandra Gennari, MD PhD

ABRAMYO Phase I-II study of weekly nab paclitaxel in combination with liposomal encapsulated doxorubicin in patients with HER2 negative MBC Alessandra.

BIBF 1120 (Nintedanib) in platinum-resistant ovarian cancer:

PHASE I/II STUDY OF PEGYLATED LIPOSOMAL DOXORUCIN (PLD) AND GEMCITABINE (GEM) IN RECURRENT PLATIN RESISTANT OVARIAN CANCER (OC). A Study of the VWOG.

Gajria D et al. Proc SABCS 2010;Abstract P

NCI/CTEP 7435: Eribulin Active, Tolerable in Urothelial Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 - June 2,

Oki Y et al. Proc ASH 2013;Abstract 252.

Vahdat L et al. Proc SABCS 2012;Abstract P

Mateos MV et al. Proc ASH 2013;Abstract 403.

Intervista a Lucio Crinò

LV5FU2-cisplatin followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: Preliminary results of a randomized phase III trial (FFCD.

1University Hospital Gasthuisberg, Leuven, Belgium;

Presentation transcript:

EORTC OSN/CTOS11 Safety of Caelyx combined with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas. Final data of an EORTC phase I study. O.S. Nielsen, P. Reichardt, D. Pink, J. Lindegaard, S. Daugaard, C. Hermans, K. Stoichkov, M. van Glabbeke, I. Judson. CTOS 11th Annual Meeting 2005 Boca Raton, Florida

EORTC OSN/CTOS11 BACKGROUND Caelyx (pegylated liposomal doxorubicin) 40 mg/m 2 q 4 weeks seems to have the same efficacy in adult soft tissue sarcomas (STS) as doxorubicin with an improved toxicity profile (EORTC and others). It could thus be an alternative to doxorubicin and may well be easier to combine with agents such as Ifosfamide.

EORTC OSN/CTOS11 Study design Main eligibility criteria: Progression within 6 weeks, no previous chemotherapy, PFS < 2, years and adequate cardiac, liver, renal and haematological function. Treatment: Caelyx as a 1 hr i.v. infusion d1 and Ifosfamide+mesna as a 4-hr i.v. infusion d1-3 every 3 weeks: Dose level I: Caelyx 30 mg/m² + Ifosfamide 1.7 g/m² d 1-3 Dose level 2: Caelyx 30 mg/m² + Ifosfamide 2 g/m² d 1-3 Dose level 3: Caelyx 30 mg/m² + Ifosfamide 2.5 g/m² d 1-3 Dose level 4: Caelyx 30 mg/m² + Ifosfamide 3 g/m² d 1-3 Dose level 5: Caelyx 40 mg/m² + Ifosfamide 3 g/m² d 1-3 Cohorts of 3 pts/dose level. DLT 1/3 pts a new cohort added. Evaluation after 2 treatment cycles. Non-evaluable pts replaced. Max. 6 cycles

EORTC OSN/CTOS11 ENDPOINTS Main endpoint: Toxicity (CTC). Occurrence of DLT: ANC < 0.5 x 10 9 lasting ≥ 7 days or ≥ 3 days + fever at least 38.5 o C, grade 4 thrombocytopenia, any grade 3-4 toxicity except nausea, vomiting and alopecia, and any toxicity requiring a 2 week treatment delay. Secondary endpoint: Objective response in patients with measurable disease (RECIST).

EORTC OSN/CTOS11 ACCRUAL 5 pts not evaluable for response (only 1 cycle of treatment)

EORTC OSN/CTOS11 Baseline characteristics Male/female:12/16 Median age: 60 years (29-69) PS: 75% PS 1 Leiomyos: 10 pts

EORTC OSN/CTOS11 RESULTS: Dose Limiting Toxicities Dose levelToxicityType DLT 5 Dyspnea + allergic reactionClinical 5 Thrombocytopenia + renal insufficiencyCombination 5 Febrile neutropeniaCombination 5 Febrile neutropenia Combination 5 Febrile Neutropenia Combination 5 Thrombocytopenia Combination Recommended dose level = 4: ( Caelyx 30 mg/m² + Ifosfamide 3 g/m² d 1-3)

EORTC OSN/CTOS11 Hematological toxicities Recommended dose level 4 Grade01234Total Leucopenia Granulocytopenia Thrombocytopenia 516 Anaemia 156

EORTC OSN/CTOS11 Non-hematological toxicities Recommended dose level 4 Grade01234Total Oedema 2226 Fatigue 426 PPE 66 Other skin tox 4116

EORTC OSN/CTOS11 Efficacy evaluation Currently, 4 pts alive + progression free, 5 pts alive + PD. All deaths were due to progression.

EORTC OSN/CTOS11 Overall and progression free survival (months) ONNumber of patients at risk :Failure OS PFS Median OS~ 11 months Median PFS~ 6 months

EORTC OSN/CTOS11 CONCLUSIONS 6 DLTs were observed amongst the 7 pts treated at dose level 5. No DLT was reported at any other dose level. Therefore, dose level 4 is the recommended dose for further trial, i.e. Caelyx 30 mg/m² + Ifosfamide 3 g/m² d PR were observed; the estimated median PFS was ~ 6 months (equivalent to 1st line doxorubicin based therapy), and the estimated median survival approximately 11 months. Combined Caelyx and Ifosfamide seems to be feasible in patients with advanced soft tissue sarcomas and this combination may allow to give Ifosfamide at a dosage similar to that used when given alone. BUT …… PR at dose level 5 (not level 4)! Caelyx is expensive! Hematopoietic growth factors? Further data needed – if possible.